Although selective metabolic and receptor-based molecular agents will surely be included in the future of prostate cancer diagnosis and therapy, currently available inorganic compounds-such as 18 F-NaF for the diagnosis of bony disease and 223 RaCl 2 for the therapy of bone metastases-were recently shown to be superior to standard 99m Tcphosphonates for diagnosis and 153 Sm-ethylenediaminetetramethylene phosphonate or 89 SrCl 2 for therapy. The advantages of 18 F-NaF include improved lesion detection and, when used in combination with CT, improved diagnostic confidence and specificity. In addition to being the first approved α-emitter, 223 RaCl 2 is the first radiopharmaceutical to show an increase in overall survival, a decrease in skeletal events, palliation of bone pain, and a low profile of adverse reactions (which are mild and manageable). The management of metastatic bone disease with 223 RaCl 2 is uniquely satisfying, as patients can be monitored directly during their monthly treatment visits.
TheAmer ican Cancer Society has estimated that there will be 180,890 new prostate cancer (PC) patients and 28,170 deaths in 2016 (1) . Prostate cancer ranges from asymptomatic to a progressive systemic malignancy. Lymph nodes and bones are the most common sites of metastases. Serum prostate-specific antigen (PSA) levels, Gleason score, and clinical stage at presentation are used to assess pretreatment risk and the probability of recurrence or metastases. On the basis of these criteria, patients are characterized as having low risk (bone metastases unlikely) or high risk (bone metastases likely). Skeletal metastases correlate with a poor prognosis. 99m Tc-methylene diphosphonate ( 99m Tc-MDP) scintigraphy has been the imaging method of choice for the evaluation of predominantly sclerotic skeletal PC metastases. However, the growing availability of PET imaging systems, the establishment of commercial regional distribution centers for PET radiotracers, and the relatively recent concerns with shortages of 99m Tc-labeled radiotracers have prompted much interest in the use of PET in this clinical setting (2).
F-NAF PET IN PC
18 F-NaF is a positron-emitting radiopharmaceutical that was used for skeletal scintigraphy in the 1970s. Clinical use was limited then because of logistic difficulties in delivering tracers with a half-life of 110 min and the absence of PET technology. 18 F-NaF was replaced in the late 1970s by 99m Tc-labeled phosphonates, which had improved g-camera compatibilities (3, 4) . As an analog of the hydroxyl group found in hydroxyapatite bone crystals, 18 FNaF is an avid bone seeker. Ion exchange is its mechanism of uptake, and blood flow is the rate-limiting step in the transfer of fluoride ions from blood to bone (4, 5) . As with 99m Tc-phosphonates, which adhere to bone by chemisorption, fluorine is directly incorporated into the bone matrix, converting hydroxyapatite to fluoroapatite (6) . 18 F-NaF is rapidly cleared from plasma, with only 10% of 18 F-NaF remaining in plasma at 1 h (7, 8) . This desirable characteristic of rapid blood clearance in association with fast and high bone uptake leads to high-quality (high targetto-background uptake ratio) skeletal images in less than 1 h after intravenous 18 F-NaF administration (Fig. 1) . Nonuniform uptake of 18 F-NaF in normal skeleton reflects differential regional blood flow and bone crystal surface nonuniformity. Regional high uptake in abnormal scans corresponds to processes that increase blood flow to the exposed bone crystal surface.
F-NAF PET/CT VS. 99M TC-MDP BONE SCINTIGRAPHY
18 F-NaF PET/CT is currently under evaluation for the detection of malignant skeletal lesions. In December 2015, the Centers for Medicare & Medicaid Services issued a decision memorandum regarding the use of 18 F-NaF PET for the detection of bony metastasis, concluding that available outcome evidence was not sufficient to allow for 18 F-NaF PET reimbursement (9) . The Centers for Medicare & Medicaid Services recommended continuation of coverage with evidence development for another 2 y, as before, through the National Oncologic PET Registry for 18 F-NaF (9). 99m Tc-MDP bone scintigraphy has been the method of choice for the evaluation of osseous metastases, as it enables a relatively low-cost whole-skeleton survey. Applications of skeletal scintigraphy include initial staging, monitoring the response to therapy, and detection of areas at risk for pathologic fracture. Although 99m Tc-MDP scintigraphy is sensitive for the detection of advanced skeletal metastatic lesions, early involvement may be missed because this technique relies on identification of the osteoblastic reaction of the involved bone rather than detection of the tumor itself. The technique relies significantly on regional blood flow to bone. Spatial resolution limitations imposed by planar scintigraphy and SPECT also affect bone scintigraphy sensitivity for osseous metastases (10) . In a study by Even-Sapir (11), patients with high-risk PC underwent 99m Tc-MDP bone scintigraphy with SPECT and 18 F-NaF PET/CT. In a patient-based analysis, the sensitivities of 99m Tc-MDP planar scintigraphy, SPECT, and 18 FNaF PET/CT were 70%, 92%, and 100%, respectively. The specificities of 99m Tc-MDP planar scintigraphy, SPECT, 18 F-NaF PET, and 18 F-NaF PET/CT were 57%, 82%, 62%, and 100%, respectively. Another study involving 42 PC patients demonstrated a sensitivity of 91%, a specificity of 89%, and an accuracy of 90% for 18 F-NaF PET/CT in the detection of bone metastases (12) . Cook et al. compared qualitative bone scintigraphy with semiquantitative 18 F-NaF PET for evaluation of the response to bone metastasis treatment with 223 RaCl 2 (13) and concluded that 18 FNaF PET was more accurate than 99m Tc-MDP (Fig. 2) .
A recent study comparing 18 F-NaF PET with 99m Tc-MDP scintigraphy demonstrated that 18 F-NaF PET/CT was more accurate than conventional bone scintigraphy for localizing and characterizing malignant bone lesions (14) . High-quality imaging, increased clinical accuracy, and greater patient and referring physician convenience support 18 F-NaF PET/CT in comparison with planar bone scintigraphy, SPECT, SPECT/CT, and whole-body MRI, including diffusion-weighted imaging, for the evaluation of skeletal malignancy (15, 16) . Despite the high performance of 18 F-NaF PET/CT, clinical use remains low because of limited access and nonuniform reimbursement. The exact PSA threshold for using 18 F-NaF PET/CT also remains to be established, although the threshold is probably lower than that for 99m Tc-MDP scintigraphy (typically a serum PSA level of .20 ng/mL).
Our results indicated the feasibility and utility of the combined administration of 18 F-NaF and 18 F-FDG in a single PET/CT examination for the detection of malignancy, including PC (17) (18) (19) (20) .
TARGETED RADIONUCLIDE THERAPY FOR BONE METASTASES
Initial and subsequent treatment of PC is complex and may involve surgery, radiation therapy, hormonal therapy, chemotherapy, bisphosphonates, pain medication, or a combination of these. Typically, the initial phase of hormone dependence gives way to hormone independence or castration resistance, at which time the cancer tends to metastasize more readily, especially to bone. About 90% of patients with advanced castration-resistant PC (CRPC) will develop bone metastases (21) . Bone lesions may cause pain, disability, deterioration of quality of life, and skeletal events (e.g., pathologic fractures or spinal cord compression) that may require treatment, with associated costs and potential complications. Metastatic CRPC (mCRPC) is associated with significant morbidity and mortality. Successful mCRPC treatment alleviates bone pain, reduces skeletal events, reduces disease biomarkers (such as alkaline phosphatase and PSA levels), and improves survival.
Prostate cancer cell proliferation generally induces an osteoblastic reaction in bone. One successful strategy for improving clinical outcomes in PC patients with bone metastases is the use of radiopharmaceutical agents that preferentially accumulate at sites of increased osteoblastic activity and provide a local antitumor effect (21, 22) . Targeted radionuclide therapy is used to deliver a specific amount of radioactivity to specific tissues in a certain area of the body to destroy cancer lesions (Table 1) .
SRCL 2 AND 153 SM-ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONATE ( 153 SM-EDTMP)
Historically, the most common radiopharmaceuticals for bone pain palliation in the United States were the b-emitting radiopharmaceuticals 89 SrCl 2 and 153 Sm-EDTMP. 89 SrCl 2 was approved by the U.S. Food and Drug Administration (FDA) in 1993 and has a physical half-life of 50.5 d, a maximum b-energy of 1.463 MeV (100%), and a tissue range of 8 mm. The typical dose is 148 MBq (4 mCi) through a slow intravenous push. Doses can be repeated at 3-mo intervals. Pain relief usually begins in 10-20 d and lasts up to 6 mo, resulting in reduced management expenditures (23) . Although the tumor-to-marrow absorbed dose is approximately 10:1, to avoid complications from marrow suppression, a pretreatment platelet count of greater than 60,000/mm 3 and a white blood cell count of greater than 2,400/mm 3 are suggested. With specific instructions, effective doses to bystanders are acceptable (24) . Kurosaka et al. showed that 89 SrCl 2 was effective in reducing pain, including a subset of patients who became pain-free, with resultant improvement in quality of life (25) . 89 SrCl 2 may also be effective in combination with other drugs. In a study by Tu et al., 36 patients who had CRPC and were randomly assigned to receive 89 SrCl 2 and doxorubicin had a median survival time of 27.7 mo; in contrast, for 36 patients who received doxorubicin alone, the median survival time was 16.8 mo (P 5 0.0014) (26) . However, such an outcome benefit with combined therapy was not demonstrated in patients with advanced castration-sensitive prostate cancer (27) .
153 Sm-EDTMP was approved by the FDA in 1997, emits both medium-energy b-particles and a g-photon (which allows for imaging), and has a physical half-life of 46.3 h (Fig. 3) . The recommended dose of 153 Sm-EDTMP is 37 MBq/kg (1.0 mCi/kg), administered intravenously. The patient should ingest or receive fluids and should void often to minimize bladder radiation. 153 Sm-EDTMP has a desirable combination of high bone uptake, low nonosseous uptake, and rapid blood clearance, making it useful in treating bone metastases. The highest doses are present in bone and the urinary bladder wall (28) . 99m Tc-MDP and 153 Sm-EDTMP concentrate in metastatic skeletal lesions through the same mechanisms (29) . In a phase 1 study of patients with skeletal metastases, prospective radiation dosimetry calculation permitted an accurate 153 Sm-EDTMP dosage on the basis of total red marrow exposure, starting at 100 cGy and escalating to 280 cGy, to define dose-limiting myelotoxicity (30) . Pain was relieved in 22 of 34 patients (65%) for periods ranging from 4 to 35 wk (30) . Other, larger studies confirmed similar response rates in both breast cancer and prostate cancer (31) (32) (33) . Transient myelosuppression with delayed thrombocytopenia was noted in some patients (30) . Bayouth et al. reported that radiation estimates permitted the identification of at-risk patients before myelotoxicity was reached (34) .
In 55 patients with painful bone metastases, Sartor et al. reported that repeat dosing with 153 Sm-EDTMP at 37 MBq/kg (1.0 mCi/kg) was safe and effective, and Heron et al. found that multiple treatments with 153 Sm-EDTMP had no effect on the severity of myelotoxicity (35, 36 223 RaCl 2 is primarily an a-emitter rather than a b-emitter (decay scheme: 93.5% as a-particles, ,3.6% as b-particles, and ,1.1% as g-radiation). Second, 223 RaCl 2 is the first radiopharmaceutical to show an increase in overall survival (OS), a decrease in skeletal events, palliation of bone pain, and low toxicity.
Until 2010, docetaxel was the only chemotherapeutic agent able to prolong survival after development of CRPC, and 89 SrCl 2 and a slow intravenous push) . Dosimetry was studied during a phase 1 study of 223 RaCl 2 for 3 cohorts, at 50, 100, and 200 kBq/kg. Dose rates were usually less than 2 mSv/h/MBq on contact and averaged 0.02 mSv/h/MBq at 1 m immediately after administration. Fecal excretion was the primary method of clearance, with resulting whole-body effective half-lives of 2.5-11.4 d (Fig. 4) (45-47) .
a-particles require relatively minimal radiation safety precautions (48) . For example, in the average patient receiving 3.5 MBq (95 mCi) of 223 RaCl 2 , the dose measures 0.35 mSv/h (0.035 mrem/h) at 1 m. Thus, no contact precautions are associated with 223 RaCl 2 . Similar to recommendations for 131 I therapy, bathroom precautions are recommended for 1 wk to minimize radiation exposure to others; these precautions include multiple flushing, area cleanup, and hand washing.
An early phase 2 study (49) was done to investigate the doseresponse relationship and pain-relieving effect of 223 RaCl 2 . In that study, 100 mCRPC patients were randomized to receive a single 223 RaCl 2 dose of 5, 25, 50, or 100 kBq/kg. The pain index 2 wk after 223 Ra administration was significantly related to the dose (P 5 0.035). At week 8, there were 40%, 63%, 56%, and 71% pain responders in the groups receiving 5, 25, 50, and 100 kBq/kg, respectively. All doses were considered safe, and a decrease in the bone alkaline phosphatase level in the group receiving the highest dose was noted (P 5 0.0067).
In another phase 2 study, the efficacy and safety of 223 RaCl 2 at 3 different doses were evaluated in mCRPC patients (50) . In this phase 2 double-blind multicenter study, 122 patients were randomized to receive 3 injections of 223 Ra at 6-wk intervals: 25 kBq/kg (n 5 41), 50 kBq/kg (n 5 39), and 80 kBq/kg (n 5 42). The primary endpoint was reached, with a statistically significant dose-response relationship, for no patients (0%) in the group receiving 25 kBq/kg, for 2 patients (5%) in the group receiving 50 kBq/kg, and for 5 patients (12%) in the group receiving 80 kBq/kg (P 5 0.0297). A decrease in the bone alkaline phosphatase level of greater than or equal to 50% was identified in 6 patients (16%), 24 patients (67%), and 25 patients (66%) in the groups receiving 25, 50, and 80 kBq/kg, respectively (P , 0.0001). The most common treatment-related adverse events occurring up to wk 24 across all dose groups were diarrhea (21%), nausea (16%), and anemia (14%). No difference in the incidences of hematologic events was seen among the dose groups. 223 RaCl 2 was well tolerated at all doses and had a dose-dependent effect on serum CRPC activity markers.
Final approval of 223 RaCl 2 followed the phase 3 ALSYMPCA (Alpharadin in Symptomatic PC) trial (51) . In this randomized, double-blind, placebo-controlled study, 921 patients who had received, were not eligible to receive, or declined docetaxel (in a 2:1 ratio) were randomized to receive six injections of 223 (54) . Both patients and physicians should be aware of this potential unlinking of OS and PSA in mCRPC so that therapy is not unnecessarily stopped prematurely. On the basis of phase 2 and 3 trials, the most common (.10%) adverse reactions in patients receiving 223 RaCl 2 were nausea, diarrhea, vomiting, and peripheral edema. The most common hematologic abnormalities were anemia, lymphocytopenia, leukopenia, thrombocytopenia, and neutropenia (52) . One study reviewed the 1-y clinical experience with 223 RaCl 2 in 25 mCRPC patients (55) . About one-quarter of the cohort completed the entire 6-dose treatment cycle. Advancing soft-tissue disease was the primary reason for the cessation of therapy. Adverse events were mild and manageable. A decline in the serum alkaline phosphatase level was more common than a decline in the PSA level. Another retrospective investigation reviewed the clinical experience after 532 cycles of 223 RaCl 2 administration in 110 patients (56) . That study showed that there were significant reductions in the serum alkaline phosphatase level and pain score and that progression risk was associated with a decrease in the serum PSA doubling time. Simultaneous external-beam radiation therapy was associated with an increased risk of bone marrow failure.
The effectiveness of 223 RaCl 2 therapy was recently evaluated in relation to skeletal tumor burden on whole-body 18 F-NaF PET/CT (57) . In 42 patients, skeletal tumor burden indices derived from PET/CT at baseline were highly correlated and were significant independent predictors of OS. In an earlier study, an SUV max threshold of 10 was shown to exclude nearly all normal bone activity from volumetric calculations (58) .
CONCLUSION
18 F-NaF PET provides superior diagnostic performance compared with 99m Tc-MDP bone scintigraphy for the evaluation of patients with PC. Radionuclide therapy for painful bone metastases is undergoing a significant resurgence because of the introduction of 223 Ra and the use of radiopharmaceuticals in combination with standard chemotherapy. These developments will contribute significantly to the care of patients with PC in the era of personalized and precision medicine (59).
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